JPWO2020146666A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020146666A5 JPWO2020146666A5 JP2021540019A JP2021540019A JPWO2020146666A5 JP WO2020146666 A5 JPWO2020146666 A5 JP WO2020146666A5 JP 2021540019 A JP2021540019 A JP 2021540019A JP 2021540019 A JP2021540019 A JP 2021540019A JP WO2020146666 A5 JPWO2020146666 A5 JP WO2020146666A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- formulated
- skin
- damage
- radiation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 229960004308 ACETYLCYSTEINE Drugs 0.000 claims 4
- UJCHIZDEQZMODR-SCSAIBSYSA-N Acetylcysteinamide Chemical compound CC(=O)N[C@H](CS)C(N)=O UJCHIZDEQZMODR-SCSAIBSYSA-N 0.000 claims 4
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 229940095259 Butylated Hydroxytoluene Drugs 0.000 claims 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- LNTHITQWFMADLM-UHFFFAOYSA-N Gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims 2
- 206010040829 Skin discolouration Diseases 0.000 claims 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L Sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims 2
- 201000004569 blindness Diseases 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 201000004624 dermatitis Diseases 0.000 claims 2
- 231100000406 dermatitis Toxicity 0.000 claims 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000037380 skin damage Effects 0.000 claims 2
- 230000036559 skin health Effects 0.000 claims 2
- 230000002087 whitening Effects 0.000 claims 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- DVOVBGJJSFSOPZ-UHFFFAOYSA-N 2-acetamidopropanamide Chemical compound NC(=O)C(C)NC(C)=O DVOVBGJJSFSOPZ-UHFFFAOYSA-N 0.000 claims 1
- 208000009043 Chemical Burns Diseases 0.000 claims 1
- 229960001305 Cysteine Hydrochloride Drugs 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 229940074391 Gallic acid Drugs 0.000 claims 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims 1
- 229940067606 Lecithin Drugs 0.000 claims 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims 1
- 108009000578 Oxidative Stress Proteins 0.000 claims 1
- 229940100996 SODIUM BISULFATE Drugs 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 208000006641 Skin Disease Diseases 0.000 claims 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M Sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 claims 1
- 206010053615 Thermal burn Diseases 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Vitamin C Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N [(1R)-1-carboxy-2-sulfanylethyl]azanium;chloride;hydrate Chemical compound O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 claims 1
- 229940087168 alpha Tocopherol Drugs 0.000 claims 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 1
- 235000010323 ascorbic acid Nutrition 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 239000011668 ascorbic acid Substances 0.000 claims 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000004515 gallic acid Nutrition 0.000 claims 1
- 239000000787 lecithin Substances 0.000 claims 1
- 235000010445 lecithin Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000008185 minitablet Substances 0.000 claims 1
- 230000004297 night vision Effects 0.000 claims 1
- 230000036542 oxidative stress Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 claims 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 claims 1
- 235000010262 sodium metabisulphite Nutrition 0.000 claims 1
- 235000010265 sodium sulphite Nutrition 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 230000036561 sun exposure Effects 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 229960001367 tartaric acid Drugs 0.000 claims 1
- 239000011975 tartaric acid Substances 0.000 claims 1
- 235000002906 tartaric acid Nutrition 0.000 claims 1
- 230000036575 thermal burns Effects 0.000 claims 1
- 229960000984 tocofersolan Drugs 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
- 201000006083 xeroderma pigmentosum Diseases 0.000 claims 1
- 239000002076 α-tocopherol Substances 0.000 claims 1
- 235000004835 α-tocopherol Nutrition 0.000 claims 1
Claims (8)
- 放射線皮膚炎、皮膚ライトニング、放射線による皮膚への損傷のうちの少なくとも１つの予防及び治療、ホワイトニング、又は皮膚の健康の改善を必要とするヒト対象における放射線皮膚炎、皮膚ライトニング、放射線による皮膚への損傷のうちの少なくとも１つの予防及び治療、ホワイトニング、又は皮膚の健康の改善のための薬剤であって、治療有効量のＮ－アセチルシステイン（ＮＡＣ）、Ｎ－アセチルシステインアミド（ＮＡＣＡ）、又は（２Ｒ、２Ｒ'）－３，３'－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉＮＡＣＡ）を含む、前記薬剤。
- ＮＡＣ、ＮＡＣＡ、又はｄｉＮＡＣＡが、以下の少なくとも１つに該当するように製剤化された、請求項１に記載の薬剤。
薬学的に許容される担体中において、又は薬学的に許容される担体と共に製剤化された；
経口、静脈内、筋肉内、経腸、眼内、網膜下、硝子体内、局所、眼、舌下、皮膚、皮下、又は直腸内に投与されるように製剤化された；
約０．５～１５０ｍｇ／Ｋｇの１日用量で製剤化された；
１日２回又は３回の投与用に製剤化された；
第２の活性薬剤と共に製剤化された；
１用量当たり１００、１５０、１５０、３００、３３３、４００、５００、６００、７００、７５０、８００、９００、１，０００、２，５００、５，０００、７，５００、又は１０，０００ｍｇで製剤化された；
ミニ錠剤、カプセル、錠剤、発泡剤、デュアル放出、混合放出、サシェ、粉末、又は液剤に製剤化された； - ＮＡＣ、ＮＡＣＡ、又はｄｉＮＡＣＡが、アスコルビン酸、システイン塩酸塩、硫酸水素ナトリウム、二亜硫酸ナトリウム、亜硫酸ナトリウム、パルミチン酸アスコルビル、ブチル化ヒドロキシアニソール（ＢＨＡ）、ブチル化ヒドロキシトルエン（ＢＨＴ）、レシチン、没食子酸プロピル、α－トコフェロール、クエン酸、エチレンジアミン四酢酸（ＥＤＴＡ）、ソルビトール、酒石酸、又はリン酸のうちの少なくとも１つから選択される第２の活性薬剤と共に投与される、請求項２に記載の薬剤。
- 治療有効量が、好ましくは、夜間視力の欠損、全体的な視力の欠損、視野の欠損のうちの少なくとも１つを、２週間、１カ月、２カ月、３カ月、６カ月、１年、２年、又は５年のうちの少なくとも１つから選択される規定された期間にわたり、未治療の対照対象と比較して少なくとも１０％、少なくとも１５％、少なくとも２０％、少なくとも２５％、少なくとも３０％、少なくとも３５％、少なくとも４０％、少なくとも４５％、少なくとも５０％、少なくとも５５％、少なくとも６０％、少なくとも６５％、少なくとも７０％、少なくとも７５％、少なくとも８０％、少なくとも８５％、少なくとも９０％、少なくとも９５％、又はそれ以上減少させる治療薬の量を意味する、請求項１に記載の薬剤。
- 日光曝露からの放射線による皮膚への損傷を防ぐための薬剤である、請求項１に記載の薬剤。
- 生物兵器への曝露、化学熱傷、熱傷、摩擦によって引き起こされる接触損傷を防ぐための薬剤である、請求項１に記載の薬剤。
- 色素性乾皮症を治療するための薬剤である、請求項１に記載の薬剤。
- 酸化的ストレスによって引き起こされるその他の皮膚障害を治療するための薬剤である、請求項１に記載の薬剤。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962791422P | 2019-01-11 | 2019-01-11 | |
| US62/791,422 | 2019-01-11 | ||
| PCT/US2020/012975 WO2020146666A1 (en) | 2019-01-11 | 2020-01-09 | N-acetylcysteine amide (naca) and (2r,2r')-3,3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022518174A JP2022518174A (ja) | 2022-03-14 |
| JPWO2020146666A5 true JPWO2020146666A5 (ja) | 2023-01-20 |
Family
ID=71521154
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021540019A Pending JP2022518174A (ja) | 2019-01-11 | 2020-01-09 | 放射線皮膚炎の予防及び治療、並びに皮膚ライトニング、皮膚ホワイトニング、並びに皮膚改善のためのｎ－アセチルシステインアミド（ｎａｃａ）及び（２ｒ，２ｒ’）－３，３’－ジスルファンジイルビス（２－アセトアミドプロパンアミド）（ｄｉｎａｃａ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220105056A1 (ja) |
| EP (1) | EP3908271A4 (ja) |
| JP (1) | JP2022518174A (ja) |
| KR (1) | KR20210114460A (ja) |
| CN (1) | CN113573704A (ja) |
| WO (1) | WO2020146666A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190135741A1 (en) | 2017-11-09 | 2019-05-09 | Nacuity Pharmaceuticals, Inc. | Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress |
| EP3908341A4 (en) | 2019-01-11 | 2022-03-02 | NaCuity Pharmaceuticals, Inc. | TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA) |
| EP4093389A4 (en) * | 2020-01-24 | 2024-02-21 | NaCuity Pharmaceuticals, Inc. | PRODRUG FOR THE TREATMENT OF DISEASES AND INJURIES OF OXIDATIVE STRESS |
| WO2024013711A1 (en) | 2022-07-15 | 2024-01-18 | Universidade De Coimbra | Topical composition and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080028357A (ko) * | 2005-04-21 | 2008-03-31 | 글렌 에이. 골드스타인 | 산화성 스트레스에 관련된 질병 및 증상 치료용ｎ-아세틸시스테인 아미드(ｎａｃ 아미드) |
| WO2011044230A2 (en) * | 2009-10-06 | 2011-04-14 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions |
| EP2397125A1 (en) * | 2010-06-15 | 2011-12-21 | Histocell, S.L. | Antioxidant composition |
| WO2013138744A1 (en) * | 2012-03-16 | 2013-09-19 | M. Alphabet 1, Llc | Compositions for the treatment of skin disorders |
| CN108618993B (zh) * | 2018-07-16 | 2021-07-27 | 广东格烯生物科技股份有限公司 | 一种美白组合物及其制备方法和应用 |
-
2020
- 2020-01-09 EP EP20738196.3A patent/EP3908271A4/en active Pending
- 2020-01-09 US US17/421,308 patent/US20220105056A1/en active Pending
- 2020-01-09 WO PCT/US2020/012975 patent/WO2020146666A1/en unknown
- 2020-01-09 JP JP2021540019A patent/JP2022518174A/ja active Pending
- 2020-01-09 KR KR1020217025541A patent/KR20210114460A/ko not_active Application Discontinuation
- 2020-01-09 CN CN202080017282.XA patent/CN113573704A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice | |
| JP2020023549A5 (ja) | ||
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| RU2003126257A (ru) | Твердая дозированная лекарственная форма для орального введения, содержащая комбинацию метформина и глибенкламида | |
| RU2003131876A (ru) | Композиции n-ацетилцистеина и способы лечения и профилактики токсичности лекарственных средств | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JP2005508840A5 (ja) | ||
| US6498247B2 (en) | Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions | |
| US8808763B2 (en) | Methods for improving sleep efficiency in healthy human beings | |
| US4314989A (en) | Methionine sulfoxide amflioration of acetaminophen toxicity | |
| JP2023171776A (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| Dougherty et al. | Gabapentin: a unique anti-epileptic agent | |
| JPH04243825A (ja) | 色素沈着症治療剤 | |
| US20110288145A1 (en) | Novel Formulation For L-Tryptophane Comprising Carbidopa/Benserazide | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JPWO2020146666A5 (ja) | ||
| Tanaka et al. | Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia | |
| Wakai et al. | Landau-Kleffner syndrome and sulthiame | |
| US3019165A (en) | Sunburn preventive and burn remedy | |
| EP2830605B1 (en) | A combination medicament comprising phenylephrine and paracetamol | |
| JP2004091473A (ja) | 色素沈着改善治療薬 | |
| Gasser et al. | Comparative single-and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy subjects | |
| Maynard et al. | Acetylsalicyclate administered during simulated ischemia reduces the recovery of neuronal function in the in vitro rabbit retina | |
| JPH04342528A (ja) | アルコール代謝およびアセトアルデヒド代謝促進剤 | |
| GB2510444A (en) | Enhanced combination of phenylephrine and paracetamol |